Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: A systematic review

Katherine B. Winfree,Claire Ainsworth,Annete Njue,Cliff Molife,Matthew Lyall,Min Hua Jen,Marisa A. Bittoni,Anne Heyes,David P. Carbone

Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: A systematic review

2018

Katherine B. Winfree
Claire Ainsworth
Annete Njue
Cliff Molife
Matthew Lyall
Min Hua Jen
Marisa A. Bittoni
Anne Heyes
David P. Carbone

e21120Background: This review aimed to summarize the clinical utility (efficacy, safety, and quality of life) of ramucirumab compared to nintedanib, immune checkpoint inhibitors (ICIs), and chemoth...

Keywords:

Cancer research
Pathology
Disease
Chemotherapy
Medicine
Immune checkpoint
Quality of life
in patient
Ramucirumab
Oncology
immune checkpoint inhibitors
aggressive disease
Internal medicine
Nintedanib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations